MAPT and Alzheimer disease: However, biomarkers of amyloid and tau do not accurately predict the extent of cognitive impairment, with some cognitively impaired individuals often showing normal amyloid levels, and 30–40% of cognitively unimpaired elderly individuals showing AD pathology1, 22.